TFF3 and breast carcinoma: Furthermore, TFF3 has been implicated in reduced sensitivity and acquired resistance to chemo-, hormonal, and targeted therapies in different cancers; and in particular, mammary carcinoma with acquired trastuzumab resistance exhibited a shift in oncogene addiction from HER2 to TFF38,10,21.